Australian Senate clears Medical Future Fund, sending it back to House for amendments

12 August 2015
australia-big

The Australian government’s A$20 billion ($14.64 billion) landmark Medical Research Future Fund bill has cleared the Senate, and the Abbott administration is claiming it will be the largest of its kind in the world.

It passed through with 20 amendments to the legislation, including tighter controls over how the money would be distributed. This means it must return to the House of Representatives for approval.

The fund will receive an initial contribution of A$1 billion from the currently uncommitted balance of the Health and Hospitals Fund and will eventually provide around A$1 billion per annum in additional funding for medical research and medical innovation. The rest of the contributions will come from the savings from the health portfolio of the 2014-2015 Budget which have already passed, or will pass through parliament in the future, until the balance reaches $20 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight